Industry Focus Transcripts

Celgene's and Gilead Sciences’ Q2 2017 results are fueling gains in their stock prices, but is one of these stocks doing better than the other?

This quarter’s earnings had two of the world’s biggest companies moving multiple percentage points on some significant trends.

Shopify and its founder, Tobias Lutke, have been Fool favorites for a long time. On this episode we talk about why, despite the stock's crazy run over the past year, we'd still buy shares of this e-commerce company.

Renewable energy is taking off in some parts of the world, but it's far from replacing fossil fuels. And speaking of fossil fuels, the Industry Focus: Energy team checks in with OPEC, and some infrastructure and service players as well.

Chipotle is reporting earnings tonight -- here's what to expect, and what numbers you’ll want to pay attention to.

Small-cap stocks Novocure, Flexion Therapeutics, and Zogenix want to shake up healthcare, and investors are optimistic about their chances.

The cast fields listener questions to dig into the outlook for mall-based apparel chain Buckle before exploring the $30 billion private label brand, Kirkland Signature.

OPEC’s production cut compliance continues to drop, is this the end of its attempt to prop up oil prices?

After Puma Biotech's recent success, the search is on for other clinical-stage biotechs being run by proven CEOs. Could leadership experience turn Aurinia Pharmaceuticals, Axovant Sciences, and Esperion Therapeutics into winners too?

Some IPOs, especially tech ones, balloon up to three times their valuation on opening day, but investors would be wise to wait a few quarters before diving in.

We all make investing mistakes, but buying a commodity producer lacking a cost advantage shouldn’t be one of them.

Only 10% of clinical-stage drugs make it across the FDA finish line, and that makes buying preclinical biotech stocks the riskiest game in town.

We explain the major hurdles day traders and speculators face in their pursuit of easy profits.

We dig into things we'd never do -- or, at least, that we try to avoid. This includes investing advice, as well as pointers about life more generally.

Working a summer or part-time job this year can help teach kids about money, careers paths, and more.

Is being "better late than never" true for America's biggest oil major?

Looking for a beach read or a podcast to pass the time on the family trip? We run through some of our favorite tech books and shows so you can still get your fix during the slow months of summer.

Solar stocks are finally rallying after a year of malaise. Is this the long-rumored rebound?

The average investor has a wealth of information at their fingertips -- they just need to know where to find it.

Rite Aid’s shares crashed after Walgreens abandoned plans to buy it lock, stock, and barrel. Will this misstep give Amazon.com a chance to disrupt the prescription drug market?